A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

Launched by PFIZER · Dec 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a vaccine called Prevenar 20, which helps protect against certain types of pneumonia. The trial is looking for participants in South Korea, including infants as young as 6 weeks old, children, teenagers, and adults who have been prescribed this vaccine by their doctor. In total, anyone aged 6 weeks and older can join the study, as long as they meet certain health guidelines.

Participants will receive a single dose of the Prevenar 20 vaccine, which will be given as an injection in the shoulder. The study lasts for 28 days, during which doctors will check how participants feel and any side effects they might experience. If participants cannot visit the clinic in person after the vaccine is given, the doctors can collect information through phone calls or emails. This research will help ensure that the vaccine is safe for those who receive it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:
• • 1. Infant, children and adolescents who are aged 6 weeks to under 18 years or adult who are 18 years or older
• • 2. Subjects who have been prescribed Prevenar 20 by their physician as per approved product label
• • 3. Evidence of a personally signed and dated informed consent document indicating that the subject or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study
• Exclusion Criteria:
• Subjects meeting any of the following criteria will not be included in the study:
• • 1. Subjects with contraindication according to approved label of Prevernar 20 (Pneumococcal 20-valent conjugate vaccine)
• • 2. Any subjects (or a legally acceptable representative) who do not agree that Pfizer and companies working with Pfizer use his/her information